Table 1: Therapeutic applications of bone marrow derived-stem cells in liver cirrhosis patients.

Cell type Dose Route Sample size (n) Outcome Reference
BM Single median dose/1 × 108 Hepatic artery 10 Increased serum albumin; Decreased bilirubin [22]
BM Single median dose/240-1027 × 106 Intravenous 22 Increased serum albumin; Decreased bilirubin and ascites [34]
BM Single median dose/5.2 × 109 Peripheral vein 9 Increased serum albumin; Decreased CPS [20]
BM Single median dose/0.48-1.48 × 108/kg body weight Peripheral vein 10 Increased serum albumin; Decreased ascites [11]
BM Single median dose/8 × 109 Peripheral vein 5 Increased serum albumin and protein; Decreased prothrombin time [35]
BM Single median unspecified dose Hepatic artery 30 Increased serum albumin; Decreased CPS [72]